摘要
吉西他滨30分钟静脉滴注是晚期胰腺癌的标准治疗方案。为了更好的提高吉西他滨的疗效和改善胰腺癌患者的预后,临床上正在进行各种试验:更改用药方法;与其它化疗药物联合应用或替换为更有效的化合物。本文以互连网上注册的临床试验数据库(www.clinicaltrials.gov)为主要来源,检索了目前美国已注册的、正在进行的有关胰腺癌的临床试验,将其略作整理分类作一综述。
Gemcitabine （iv over 30 minutes） is the standard therapy for inoperable pancreatic cancer of advanced stage. In order to improve the effect of gemcitabine and the prognosis of pancreatic cancer, lots of clinical trials are being conducted, i.e. to change the method of administration, combine with other drugs, or to be replaced by other more efficient drugs. The article summarizes the ongoing clinical trials in American at present, that can be searched at data base of the clinical trials on internet （www.clinicahrials.gov）.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2005年第20期1197-1199,共3页
Chinese Journal of Clinical Oncology
关键词
胰腺肿瘤
药物
台疗
临床试验
吉西他滨
Pancreatic cancer Clinical trials Gemcitabine Chemotherapy
